ImmuCell Corporation (ICCC) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
Les analystes estiment Bénéfice par action (EPS) de $-0.11 et chiffre d'affaires de $0.02B pour le prochain exercice fiscal.
Historique du Bénéfice par action (EPS): 2024: réel $-0.26 vs est $-0.11 (manqué -136.4%). 2025: réel $-0.12 vs est $-0.24 (dépassé +50%). Précision des analystes: 21%.
Estimations du BPA — ICCC
21%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.26
vs Est –$0.11
▼ 57.7% off
2025
Actual –$0.12
vs Est –$0.24
▲ 100.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Estimations du CA — ICCC
64%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.026B
vs Est $0.019B
▲ 27.5% off
2025
Actual $0.028B
vs Est $0.015B
▲ 45.2% off
Revenue Trend
Revenue has been relatively flat. Analysts forecast revenue contraction ahead.
Les autres consultent aussi
